These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 9077073)

  • 1. [Efficacy of nasal influenza vaccine combined with Escherichia coli heat-labile enterotoxin B subunit containing a trace amount of the holotoxin in healthy volunteers].
    Hashigucci K; Tamura S; Kurata T; Kamiya H; Ishidate T
    Kansenshogaku Zasshi; 1997 Feb; 71(2):153-61. PubMed ID: 9077073
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antibody responses in volunteers induced by nasal influenza vaccine combined with Escherichia coli heat-labile enterotoxin B subunit containing a trace amount of the holotoxin.
    Hashigucci K; Ogawa H; Ishidate T; Yamashita R; Kamiya H; Watanabe K; Hattori N; Sato T; Suzuki Y; Nagamine T; Aizawa C; Tamura S; Kurata T; Oya A
    Vaccine; 1996 Feb; 14(2):113-9. PubMed ID: 8852406
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Escherichia coli heat-labile enterotoxin B subunits supplemented with a trace amount of the holotoxin as an adjuvant for nasal influenza vaccine.
    Tamura S; Asanuma H; Tomita T; Komase K; Kawahara K; Danbara H; Hattori N; Watanabe K; Suzuki Y; Nagamine T
    Vaccine; 1994 Sep; 12(12):1083-9. PubMed ID: 7998417
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mucosal immunoadjuvant activity of recombinant Escherichia coli heat-labile enterotoxin and its B subunit: induction of systemic IgG and secretory IgA responses in mice by intranasal immunization with influenza virus surface antigen.
    Verweij WR; de Haan L; Holtrop M; Agsteribbe E; Brands R; van Scharrenburg GJ; Wilschut J
    Vaccine; 1998 Dec; 16(20):2069-76. PubMed ID: 9796066
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synergistic action of cholera toxin B subunit (and Escherichia coli heat-labile toxin B subunit) and a trace amount of cholera whole toxin as an adjuvant for nasal influenza vaccine.
    Tamura S; Yamanaka A; Shimohara M; Tomita T; Komase K; Tsuda Y; Suzuki Y; Nagamine T; Kawahara K; Danbara H
    Vaccine; 1994 Apr; 12(5):419-26. PubMed ID: 8023550
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of frequent intranasal administration of adjuvant-combined influenza vaccine on the protection against virus infection.
    Tamura S; Yajima A; Hatori E; Tamura S; Asanuma H; Suzuki Y; Aizawa C; Kurata T
    Vaccine; 1997 Nov; 15(16):1784-90. PubMed ID: 9364684
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of intranasal administration of cholera toxin (or Escherichia coli heat-labile enterotoxin) B subunits supplemented with a trace amount of the holotoxin on the brain.
    Hagiwara Y; Iwasaki T; Asanuma H; Sato Y; Sata T; Aizawa C; Kurata T; Tamura S
    Vaccine; 2001 Feb; 19(13-14):1652-60. PubMed ID: 11166888
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A proposal for safety standards for human use of cholera toxin (or Escherichia coli heat-labile enterotoxin) derivatives as an adjuvant of nasal inactivated influenza vaccine.
    Tamura SI; Kurata T
    Jpn J Infect Dis; 2000 Jun; 53(3):98-106. PubMed ID: 10957706
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influenza vaccine immunogenicity in 6- to 23-month-old children: are identical antigens necessary for priming?
    Walter EB; Neuzil KM; Zhu Y; Fairchok MP; Gagliano ME; Monto AS; Englund JA
    Pediatrics; 2006 Sep; 118(3):e570-8. PubMed ID: 16950948
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mutants of Escherichia coli heat-labile enterotoxin as an adjuvant for nasal influenza vaccine.
    Komase K; Tamura S; Matsuo K; Watanabe K; Hattori N; Odaka A; Suzuki Y; Kurata T; Aizawa C
    Vaccine; 1998; 16(2-3):248-54. PubMed ID: 9607038
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Topical imiquimod before intradermal trivalent influenza vaccine for protection against heterologous non-vaccine and antigenically drifted viruses: a single-centre, double-blind, randomised, controlled phase 2b/3 trial.
    Hung IF; Zhang AJ; To KK; Chan JF; Li P; Wong TL; Zhang R; Chan TC; Chan BC; Wai HH; Chan LW; Fong HP; Hui RK; Kong KL; Leung AC; Ngan AH; Tsang LW; Yeung AP; Yiu GC; Yung W; Lau JY; Chen H; Chan KH; Yuen KY
    Lancet Infect Dis; 2016 Feb; 16(2):209-18. PubMed ID: 26559482
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and immunogenicity of an influenza vaccine A/H5N1 (A/Vietnam/1194/2004) when coadministered with a heat-labile enterotoxin (LT) adjuvant patch.
    Glenn GM; Thomas DN; Poffenberger KL; Flyer DC; Ellingsworth LR; Andersen BH; Frech SA
    Vaccine; 2009 Dec; 27 Suppl 6():G60-6. PubMed ID: 20006142
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunization with trivalent inactivated influenza vaccine in partially immunized toddlers.
    Englund JA; Walter EB; Gbadebo A; Monto AS; Zhu Y; Neuzil KM
    Pediatrics; 2006 Sep; 118(3):e579-85. PubMed ID: 16950949
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevention of influenza by the intranasal administration of cold-recombinant, live-attenuated influenza virus vaccine: importance of interferon-gamma production and local IgA response.
    Tomoda T; Morita H; Kurashige T; Maassab HF
    Vaccine; 1995 Feb; 13(2):185-90. PubMed ID: 7625114
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mucosal (SIgA) and serum (IgG) immunologic responses in young adults following intranasal administration of one or two doses of inactivated, trivalent anti-influenza vaccine.
    Greenbaum E; Engelhard D; Levy R; Schlezinger M; Morag A; Zakay-Rones Z
    Vaccine; 2004 Jun; 22(20):2566-77. PubMed ID: 15193382
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intranasal Inactivated Influenza Vaccines: a Reasonable Approach to Improve the Efficacy of Influenza Vaccine?
    Tamura S; Ainai A; Suzuki T; Kurata T; Hasegawa H
    Jpn J Infect Dis; 2016; 69(3):165-79. PubMed ID: 27212584
    [TBL] [Abstract][Full Text] [Related]  

  • 17. IgA polymerization contributes to efficient virus neutralization on human upper respiratory mucosa after intranasal inactivated influenza vaccine administration.
    Terauchi Y; Sano K; Ainai A; Saito S; Taga Y; Ogawa-Goto K; Tamura SI; Odagiri T; Tashiro M; Fujieda M; Suzuki T; Hasegawa H
    Hum Vaccin Immunother; 2018 Jun; 14(6):1351-1361. PubMed ID: 29425074
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influenza virus vaccination of patients with chronic lung disease.
    Gorse GJ; Otto EE; Daughaday CC; Newman FK; Eickhoff CS; Powers DC; Lusk RH
    Chest; 1997 Nov; 112(5):1221-33. PubMed ID: 9367461
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and immunogenicity in man of a cell culture derived trivalent live attenuated seasonal influenza vaccine: a Phase I dose escalating study in healthy volunteers.
    Heldens J; Hulskotte E; Voeten T; Breedveld B; Verweij P; van Duijnhoven W; Rudenko L; van Damme P; van den Bosch H
    Vaccine; 2014 Sep; 32(39):5118-24. PubMed ID: 24858566
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of the trivalent influenza vaccination in Thai patients with hemodialysis or kidney transplant compared with healthy volunteers.
    Krairittichai U; Chittaganpitch M
    J Med Assoc Thai; 2013 Mar; 96 Suppl 3():S1-7. PubMed ID: 23682516
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.